Pular para o conteúdo

Biotech: A Global Overview

The biotechnology sector is a dynamic and rapidly evolving field, with certain nations emerging as leaders due to their robust research and development (R&D) ecosystems, innovative companies, and significant contributions to the global market. Here, we explore the top biotech nations, their R&D focus, and the factors propelling them to the forefront of the industry. United States: The Biotech Powerhouse With 2,840 active biotech companies and an R&D intensity added value of 17%, the United States stands as the undisputed leader in biotechnology¹. The country’s success is attributed to its strong innovation ecosystem, bolstered by venture capital, world-class research institutions, and a regulatory environment conducive to biotech development. The U.S. is particularly renowned for its advancements in medical biotechnology and pharmaceuticals. United Kingdom: Europe’s Innovation Driver The UK solidifies its position as a key player with 2,770 biotech firms and… 

more »Biotech: A Global Overview

Dieta à Base de Plantas Retarda o Progresso do Câncer de Próstata

Men with prostate cancer could significantly reduce the chances of the disease worsening by eating more fruits, vegetables, nuts, and olive oil, according to new research by UC San Francisco.  A study of more than 2,000 men with localized prostate cancer found that eating a primarily plant-based diet was associated with a 47% lower risk that their cancer would progress, compared with those who consumed the most animal products.  This amounted to eating just one or two more servings per day of healthy foods, particularly vegetables, fruits, and whole grains, while eating fewer animal products, like dairy and meat. The study followed the men, whose median age was 65 years old, over time to see how dietary factors affected the progression of their cancer.   Plant-based diets include fruits, vegetables, whole grains, nuts, legumes, vegetable oils, tea and coffee. The researchers… 

more »Plant-Based Diet Slows Prostate Cancer Progress

Dieta à base de plantas retarda progressão do câncer de próstata

Men with prostate cancer could significantly reduce the chances of the disease worsening by eating more fruits, vegetables, nuts, and olive oil, according to new research by UC San Francisco.  A study of more than 2,000 men with localized prostate cancer found that eating a primarily plant-based diet was associated with a 47% lower risk that their cancer would progress, compared with those who consumed the most animal products.  This amounted to eating just one or two more servings per day of healthy foods, particularly vegetables, fruits, and whole grains, while eating fewer animal products, like dairy and meat. The study followed the men, whose median age was 65 years old, over time to see how dietary factors affected the progression of their cancer.   Plant-based diets include fruits, vegetables, whole grains, nuts, legumes, vegetable oils, tea and coffee. The researchers… 

more »Plant-Based Diet Slows Prostate Cancer Progress

Biomarcadores de OCT retiniano e doenças neurodegenerativas

Biomarker der optischen Kohärenztomographie (OCT) werden zunehmend von Neurologen, Psychiatern und Ophthalmologen zur Diagnose, Prognose und Verlaufskontrolle neurodegenerativer Erkrankungen hinzugezogen. Zum Teil sind bereits Langzeitdaten von OCT-Biomarkern ausgewählter primärer und sekundärer neurodegenerativer Erkrankungen des zentralen Nervensystems (ZNS) wie beispielsweise der multiplen Sklerose (MS) oder M. Parkinson verfügbar. Darüber hinaus gibt es seltene neurodegenerative Erkrankungen mit frühem Krankheitsbeginn, die bereits OCT-Auffälligkeiten aufweisen können. https://link.springer.com/article/10.1007/s00347-023-01974-7

Contergan-Derivat zerstört resistente Krebszellen

Kaum ein Wirkstoff hat eine so bewegte Geschichte hinter sich wie Thalidomid. Das Molekül ist der zentrale Inhaltsstoff von Contergan, das in den 1950er-Jahren in vielen Ländern als Beruhigungs- und Schlafmittel zugelassen wurde. Doch bald stellte sich heraus, dass Schwangere, die Contergan genommen hatten, oft Kinder mit schweren Fehlbildungen zur Welt brachten. Und dennoch setzt die Medizin seit einigen Jahrzehnten wieder große Hoffnung in den Wirkstoff. Denn in Studien zeigte sich unter anderem, dass er das Wachstum von Blutgefäßen unterbindet und sich damit möglicherweise dazu eignet, Tumoren von ihrer Nährstoffversorgung abzuschneiden. Später erwies er sich außerdem als sehr effektiv für die Behandlung von Multiplen Myelomen, bösartigen Tumoren im Knochenmark. „Wir wissen inzwischen, dass Thalidomid ein sogenannter molekularer Klebstoff ist“, erklärt Dr. Xinlai Cheng vom Institut für Pharmazeutische Chemie der Universität Frankfurt. „Das heißt, der Wirkstoff hat die Fähigkeit, zwei Proteine… 

more »Contergan-Derivat zerstört resistente Krebszellen

BGI-HL OHA Lab inaugurated in Harbin

On May 10, 2024, the BGI-Heilongjiang Omics Health Axis Intelligent Laboratory (BGI-HL OHA Intelligent Laboratory) was inaugurated in Harbin, Heilongjiang province, China, marking a significant advance in the province’s efforts to address public health challenges. Utilizing the ‚13311i GigaLab‘ technological framework, this facility supports vital life and health science research, enhancing the region’s capacity to produce innovative health solutions. The ‚13311i‘ framework is at the forefront of proactive health management, integrating whole genome sequencing with analyses of blood, urine, and fecal samples and sophisticated imaging techniques such as CT, ultrasound, and MRI. With detailed health and disease risk profiles, it sets the stage for breakthroughs in early detection and personalized treatment, critical tenets of precision medicine.

Mabwell Anuncia Progresso de Teste Clínico de 9MW2821 em Câncer de Mama Triplo-Negativo

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its novel Nectin-4-targeting ADC (R&D code: 9MW2821) for triple-negative breast cancer. Based on 9MW2821’s current ongoing monotherapy clinical data, in 20 subjects with locally advanced or metastatic triple-negative breast cancer treated with the 1.25 mg/kg dose and evaluable for tumor assessment, the objective response rate (ORR) and disease control rate (DCR) were 50% and 80%, respectively, with one patient achieved CR and had been in complete response (CR) for 20 months and is currently sustained to be CR Investigational new drug application of 9MW2821 in combination with immune checkpoint inhibitor for the treatment of triple-negative breast cancer has been accepted by the China National Medical Products Administration (NMPA).

Mabwell Anuncia Progresso de Teste Clínico de 9MW2821 em Câncer de Mama Triplo-Negativo

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its novel Nectin-4-targeting ADC (R&D code: 9MW2821) for triple-negative breast cancer. Based on 9MW2821’s current ongoing monotherapy clinical data, in 20 subjects with locally advanced or metastatic triple-negative breast cancer treated with the 1.25 mg/kg dose and evaluable for tumor assessment, the objective response rate (ORR) and disease control rate (DCR) were 50% and 80%, respectively, with one patient achieved CR and had been in complete response (CR) for 20 months and is currently sustained to be CR Investigational new drug application of 9MW2821 in combination with immune checkpoint inhibitor for the treatment of triple-negative breast cancer has been accepted by the China National Medical Products Administration (NMPA).

QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results

QIAstat-Dx Respiratory Panel Plus designed for accurate diagnosis of respiratory infections, enabling detection of co-infections // Panel generates results in about one hour with less than one minute of hands-on time; offers easy access to Ct values and amplification curves // QIAGEN working on expanding QIAstat-Dx testing menu in the U.S., with a Gastrointestinal Panel currently under FDA review QIAstat-Dx Respiratory Panel Plus designed for accurate diagnosis of respiratory infections, enabling detection of co-infections // Panel generates results in about one hour with less than one minute of hands-on time; offers easy access to Ct values and amplification curves // QIAGEN working on expanding QIAstat-Dx testing menu in the U.S., with a Gastrointestinal Panel currently under FDA review QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results

QIAGEN: FDA-Zulassung für syndromischen QIAstat-Dx-Test

QIAstat-Dx Respiratory Panel Plus ist für genaue Diagnose von Atemwegsinfektionen konzipiert und ermöglicht auch Erkennung von Ko-Infektionen // Panel liefert Ergebnisse in etwa einer Stunde bei weniger als einer Minute aktiver Arbeitszeit und bietet leicht ablesbare Cycle-Threshold (Ct)-Werte sowie Amplifikationskurven // QIAGEN arbeitet an der Erweiterung des QIAstat-Dx Testmenüs in den USA; die Zulassung eines Magen-Darm-Panels wird aktuell von der FDA geprüft QIAstat-Dx Respiratory Panel Plus ist für genaue Diagnose von Atemwegsinfektionen konzipiert und ermöglicht auch Erkennung von Ko-Infektionen // Panel liefert Ergebnisse in etwa einer Stunde bei weniger als einer Minute aktiver Arbeitszeit und bietet leicht ablesbare Cycle-Threshold (Ct)-Werte sowie Amplifikationskurven // QIAGEN arbeitet an der Erweiterung des QIAstat-Dx Testmenüs in den USA; die Zulassung eines Magen-Darm-Panels wird aktuell von der FDA geprüft QIAGEN erhält FDA-Zulassung für syndromischen QIAstat-Dx-Test zur schnellen und präzisen Diagnose von Atemwegserkrankungen